Tezacaftor/VX-659/ivacaftor

N/A

Report date: 2025/07/31 17:26:22

Base Information

Drug NameTezacaftor/VX-659/ivacaftor
Drug Alias NameTezacaftor/bamocaftor/ivacaftorVX-659/TEZ/IVAVX-659/ivacaftor/tezacaftorVX-659/ivacaftor/VX-661VX-659/VX-770/VX-661
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator stimulantsCystic fibrosis transmembrane conductance regulator modulators
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[11] 
CombinationsYes TezacaftorVX-659Ivacaftor
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVertex Pharmaceuticals Incorporated
Active IndicationsN/A
Inactive IndicationsCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A